Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β

Biochemical Pharmacology

Volumn 52, Issue 11, 1996, Pages 1675-1685

  Marsh, Katherine L ^a   Willmore, Elaine ^a   Tinelli, Stella ^b   Cornarotti, Mariagrazia ^b   Meczes, Emma L ^a   Capranico, Giovanni ^b   Fisher, L Mark ^c   Austin, Caroline A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Ist Naz Stud e la Cura dei Tumori   (Italy)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

amsacrine; DNA cleavage; human DNA topoisomerase II ; human DNA topoisomerase II ; pBR322; SV40 DNA

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ISOENZYME; PLASMID DNA; RECOMBINANT ENZYME; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; DNA CLEAVAGE; DNA SEQUENCE; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; STATISTICAL ANALYSIS; YEAST;

AMINO ACID SEQUENCE; AMSACRINE; ANTINEOPLASTIC AGENTS; DNA; DNA TOPOISOMERASES, TYPE II; HUMANS; ISOENZYMES; MOLECULAR SEQUENCE DATA;

EID: 0030582837     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00516-3     Document Type: Article

References (32)

1. 1. Wang JC, DNA topoisomerases. Annu Rev Biochem 54: 665-697, 1985.
2. 2. Wang JC, Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1-9, 1987.
3. 3. Wang JC, DNA topoisomerases: Why so many? J Biol Chem 266: 6659-6662, 1991.
4. 4. Tsai Pfugfelder M, Liu LF, Liu AA, Tewey KM, Whang Peng J, Knutsen T, Huebner K, Croce CM and Wang JC, Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localisation of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85: 7177-7181, 1988.
5. 5. Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST and Mirabelli CK, Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isoenzymes. Proc Natl Acad Sci USA 86: 9431-9435, 1989.
6. 6. Austin CA and Fisher LM, Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells. FEBS Lett 266: 115-117, 1990.
7. 7. Austin CA, Sng JH, Patel S and Fisher LM, Novel HeLa topoisomerase II is the beta isoform: Complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta Gene Struct Express 1172: 283-291, 1993.
8. 8. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK and Drake FH, Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3t3 cells. Cell Growth Differ 2: 209-214, 1991.
9. 9. Capranico G, Tinelli S, Austin CA, Fisher ML and Zunino F, Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta Gene Struct Express 1132: 43-48, 1992.
10. 10. Zini N, Martelli AM, Sabatelli P, Santi S, Negri C, Ricotti GCBA and Maraldi NM, The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant. Exp Cell Res 200: 460-466, 1992.
11. 11. Petrov P, Drake FH, Loranger A, Huang W and Hancock R, Localization of DNA topoisomerase II in Chinese hamster fibroblasts by confocal and electron microscopy. Exp Cell Res 204: 73-81, 1993.
12. 12. Ross WE, DNA topoisomerases a targets for cancer therapy. Biochem Pharmacol 34: 4191-4195, 1985.
13. 13. Schneider E, Hsiang YH and Liu LF, DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21: 149-183, 1990.
14. 14. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn KW, Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12: 530-542, 1994.
15. 15. Austin CA, Patel S, Ono K, Nakane H and Fisher LM, Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem J 282: 883-889, 1992.
16. 16. Spitzner JR and Muller MT, A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acid Res 16: 5533-5556, 1988.
17. 17. Pommier Y, Capranico G, Orr A and Kohn KW, Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res 19: 5973-5980, 1991.
18. 18. Spitzner JR, In Kwon C, Gootz TD, McGuirk PR and Muller MT, Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115.953 reveals drug-dependent and -independent recognition elements. Mol Pharmacol 48: 238-249, 1995.
19. 19. Huff AC, Robinson RG, Evans AC, Selander KN, Wentland MP, Rake JB and Coughlin SA, DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives. Anti-Cancer Drug Des 10: 251-276, 1995.
20. 20. Wasserman RA, Austin CA, Fisher LM and Wang JC, Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: Expression of a functional recombinant human DNA topoisomerases IIα in yeast. Cancer Res 53: 3591-3596, 1993.
21. 21. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC and Fisher LM, Expression, domain structure and enzymatic properties of an active recombinant human DNA topoisomerase II β. J Biol Chem 270: 15739-15746, 1995.
22. 22. Fisher LM, Mizuuchi K, O'Dea MH, Ohmori H and Gellert M, Site-specific interaction of gyrase with DNA. Proc Natl Acad Sci USA 78: 4165-4169, 1981.
23. 23. Capranico G, Kohn KW and Pommier Y, Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acid Res 18: 6611-6619, 1990.
24. 24. Sander M and Hsieh TS, Drosophila topoisomerase II double-strand cleavage: analysis of DNA sequence homology at the cleavage site. Nucleic Acid Res 13: 1057-1072, 1985.
25. 25. Freudenreich CH and Kreuzer KN, Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors. EMBO J 12: 2085-2097, 1993.
26. 26. Bigioni M, Zunino F and Capranico G, Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation: Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acid Res 22: 2274-2281, 1994.
27. 27. Cornarotti M, Tinelli S, Willmore E, Zunino F, Fisher LM, Austin CA and Capranico G, Drug sensitivity and sequence specificity of human DNA topoisomerase IIα (p170) and IIβ (p180). Molec Pharmacol (in press).
28. 28. Berger JM, Gamblin SJ, Harrison SC and Wang JC, Structure and mechanism of DNA topoisomerase II. Nature 379: 225-232, 1996.
29. 29. Mirski SEL and Cole SPC, Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II α is associated with the loss of putative bipartite nuclear localisation signal in a drug-resistant human lung cancer cell line. Cancer Res 55: 2129-2134, 1995.
30. 30. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM and Holguin MH, Alterations in the topoisomerase IIa gene, mRNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II β enzyme in a mitoxantrone-resistant HL-60 human leukaemia cell line. Cancer Res 55: 1707-1716, 1995.
31. 31. Harker WG, Slade DL, Drake FH and Parr RL, Mitoxantrone resistance in HL-60 leukaemia cells: Reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase IIβ isoform. Biochemistry 30: 9953-9961, 1991.
32. 32. Dereuddre S, Frey S, Delaporte C and JacqueminSablon A, Cloning and characterization of full-length cDNAs coding for the DNA topoisomerase IIβ from Chinese hamster lung cells sensitive and resistant to 9-OH-ellipticine. Biochim Biophys Acta Gene Struct Express 1264: 178-182, 1995.